Shift Bioscience Limited

10793871

active

Private Limited Company

england wales

Companies House

Health Score

86 / 100

Healthy

30/30

Filing

20/30

Financial

36/40

Risk

2 outstanding charges (-4)

Details

SALISBURY HOUSE, CAMBRIDGE, CB1 2LA

Incorporated 30/05/2017

Compliance

Last accounts

30/06/2025

total exemption full

Next accounts due

31/03/2027

On track

Confirmation statement

Last: 13/04/2026

Due 27/04/2027

On track

Industry

72110

Research and experimental development on biotechnology

Officers

Dr Daniel Jeremy Ives

director · Since 30/05/2017

CHIEF EXECUTIVE OFFICER

BRITISH · UNITED KINGDOM · Age 39

Also on 1 other board

Dr Brendan Michael Swain

director · Since 17/01/2022

CHIEF SCIENTIFIC OFFICER

BRITISH · ENGLAND · Age 31

Alexander Thomas Pasteur

director · Since 04/02/2022

VENTURE CAPITAL INVESTOR

BRITISH · ENGLAND · Age 55

Mr Timothy Shan Rea

director · Since 11/06/2024

INVESTOR

BRITISH · ENGLAND · Age 59

Also on 10 other boards

Dr Jonathan Simon Milner

director · Since 11/06/2024

COMPANY DIRECTOR

BRITISH · ENGLAND · Age 61

Lord David Gifford Leathes Prior

director · Since 01/08/2025

GLOBAL SENIOR ADVISOR

BRITISH · UNITED KINGDOM · Age 71

Dr Laurence Edward Reid

director · Since 01/08/2025

BIOTECH ADVISOR

AMERICAN,BRITISH · UNITED STATES · Age 63

Also on 1 other board

Andrew Fraley

director · Since 13/03/2026

AMERICAN · UNITED STATES · Age 53

Persons with Significant Control

Dr Daniel Jeremy Ives

25–50% shares

25–50% votes

right-to-appoint-and-remove-directors-as-firm

British · United Kingdom · Age 39

Salisbury House, Station Road, Cambridge, CB1 2LA

Notified 30/05/2017

Charges2 outstanding

Charge

outstanding

HSBC INNOVATION BANKING

Created 11/05/2026Registered 15/05/2026

Charge

outstanding

HSBC INNOVATION BANKING

Created 25/10/2024Registered 01/11/2024

CompanyRankvs 860+ SIC 72110 peers
72

Financial strength97th percentile among SIC peers · 24/25

Employees96th percentile among SIC peers · 14/15

LiquidityCurrent ratio 10.09× · 20/20

Longevity9 years trading (max 15) · 9/15

Filing complianceAll filings up to date · 15/15

Outstanding charges -10

Show leaderboard

1Werfen Limited

2Biopharma Process Systems Limited

3Theradex (Europe) Limited

4Spicer Consulting Limited

5Exmoor Pharma Concepts Limited

6Ubc Late Stage (Uk) Limited

86Shift Bioscience Limited

How is this score calculated?

Financial strength24/25 pts

Net worth compared to all companies in the same SIC code with published accounts. Top quartile earns the full 25 points.

Employees14/15 pts

Workforce size relative to sector peers from the most recent accounts. A larger team generally signals commercial scale.

Liquidity20/20 pts

Current assets ÷ current liabilities. A ratio above 2× earns full marks; between 1–2× scores partially; below 0.5× scores minimal points.

Longevity9/15 pts

One point per year of operation since incorporation, capped at 15. Older companies have a proven track record.

Filing compliance15/15 pts

Full 15 points when both annual accounts and confirmation statement are filed on time. Points are deducted for each overdue filing.

Risk deductions

Outstanding charges: -10 pts

Maximum score is 100. Deductions apply for insolvency history, outstanding charges, going concern doubt, or disqualified officers.

Key FinancialsYear ending 30/06/2025

Net Worth

£4.3M

Balance sheet strength

Cash

£1.3M

Cash in the bank

Net Current Assets

£4.1M

Working capital

Current Assets

£4.5M

Current Liabilities

£447k

Fixed Assets

£226k

Debtors

£1.6M

18avg. employees+7

Balance Sheet

Intangible assets£10k

Assets less current liabilities£4.3M

Prepared with Caseware UK (AP4) 2024.0.164

EstimatesDerived

Year	Current Ratio	Implied Profit
2025	10.09	-£4.5M
2024	24.74	+£8.6M
2021	0.91	+£77k
2020	1.60	-£96k
2019	5.48	—

Derived from filed accounts. Not audited figures.